Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction

Biochemical and Biophysical Research Communications

Volumn 406, Issue 1, 2011, Pages 123-126

  Iwai, Masaru ^a   Kanno, Harumi ^a   Senba, Izumi ^a   Nakaoka, Hirotomo ^a   Moritani, Tomozo ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocyte differentiation; Adipose tissue; Atherosclerosis model; PPAR

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; DNA; INSULIN RECEPTOR; IRBESARTAN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ADIPOSE TISSUE DYSFUNCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL DIET; CONTROLLED STUDY; DNA BINDING; EPIDIDYMIS FAT; FOOD INTAKE; IN VIVO STUDY; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROPERITONEAL FAT; WHITE ADIPOSE TISSUE;

ADIPOCYTES, WHITE; ADIPOSE TISSUE, WHITE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; CELL COUNT; CHOLESTEROL, DIETARY; DNA; INSULIN; MALE; MICE; MICE, KNOCKOUT; PPAR GAMMA; PROTEIN BINDING; TETRAZOLES;

MUS;

EID: 79952193034     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.007     Document Type: Article

References (14)

1. Tsuchida A., Yamauchi T., Kadowaki T. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor γ, CREB-binding protein, and adiponectin. J. Pharmacol. Sci. 2005, 97:164-170.
2. Sharma A.M., Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 2007, 92:386-395.
3. DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010, 53:1270-1287.
4. Huang C., Zhang Y., Gong Z., Sheng X., Li Z., Zhang W., Qin Y. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway. Biochem. Biophys. Res. Commun. 2006, 348:571-578.
5. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004, 43:993-1002.
6. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
7. Kurtz T.W. New treatment strategies for patients with hypertension and insulin resistance. Am. J. Med. 2006, 119(5 Suppl. 1):S24-S30.
8. Tomono Y., Iwai M., Inaba S., Mogi M., Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am. J. Hypertens. 2008, 21:206-212.
9. Iwai M., Tomono Y., Inaba S., Kanno H., Senba I., Mogi M., Horiuchi M. AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am. J. Hypertens. 2009, 22:784-791.
10. Gustafson B., Hammarstedt A., Andersson C.X., Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2276-2283.
11. Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 2008, 29:2959-2971.
12. Perkins J.M., Davis S.N. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15:147-152.
13. Cooper S.A., Whaley-Connell A., Habibi J., Wei Y., Lastra G., Manrique C., Stas S., Sowers J.R. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2009-H2023.
14. Iwai M., Chen R., Imura Y., Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am. J. Hypertens. 2007, 20:579-586.